Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Yangxue Qufeng Compound (JPYXQFC) is a modern Chinese medicine formula widely used in the clinical treatment of atopic dermatitis and chronic eczema. It has demonstrated significant therapeutic effects, particularly in alleviating symptoms of atopic dermatitis. The mechanism of action involves inhibition of the TLR4/MyD88/NF-κB signaling pathway, leading to reduced expression of pro-inflammatory cytokines such as IL-6 and TNF-α, decreased serum IgE levels, and improved skin barrier function by upregulating filaggrin (FLG). JPYXQFC is typically administered as an oral decoction and has been shown to reduce dermatitis area and severity in animal models[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianpi Yangxue Qufeng Compound.